SRTA 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-06

• •continued net losses or failure to achieve or maintain profitability;

• •our ability to realize the anticipated benefits of strategic transactions, including the recently completed divestiture of the Passenger business, the acquisition and integration of Keystone (as defined below), and any future acquisitions or partnerships;

• •harm to our reputation or brand arising from operational issues, public perception, clinical outcomes or actions of third parties;

• •negative publicity, litigation, claims or regulatory scrutiny relating to our clinical services, perfusion staffing or organ recovery activities;

• •our ability to provide high-quality customer support and maintain trusted relationships with Medical Customers;

相对上期删除的文字 · 来源:10-Q · 2025-11-10

• •continued occurrence of net losses, which we have experienced since inception;

• •the impact of our recently completed divestment of the Passenger business and acquisition of Keystone (as defined below) and our ability to realize the anticipated benefits of these transactions, including the receipt of contingent consideration in connection with the sale of the Passenger business…

• •any change to the ownership of our aircraft and the operational and business challenges related thereto;

• •our reliance on contractual relationships with certain transplant centers, hospitals and Organ Procurement Organizations;

• •competition from providers with proprietary organ preservation technology or additional capabilities;

相对上期新增的文字 · 来源:10-Q · 2026-05-06

• Our primary market risk exposure is interest rate risk related to potential borrowings. Borrowings under our ABL Facility bear interest at a variable rate based on SOFR plus an applicable margin as described in Note 16 to the unaudited interim condensed consolidated financial statements included in …

• We do not have material exposure to foreign currency exchange rate risk as our operations are conducted entirely within the United States following the sale of our Passenger business in August 2025.

相对上期删除的文字 · 来源:10-Q · 2025-11-10

• There have been no material changes in market risk from the information provided in “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report on Form 10-K for the year ended December 31, 2024.